Impact of HIV and Its Treatment on Reverse Cholesterol Transport

Completed

• Conditions: HIV Infections

• Registration Number: NCT00168233
• Lead Sponsor: The Alfred

Brief Summary

To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-06
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-15
• Primary Completion: 2010-09
• Study Completion: 2011-03
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-19
• Last Update Posted: 2012-01-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 44

Inclusion Criteria

• Male patients with HIV infection (3 groups of 50 patients each)
• HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
• HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
• HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen

Exclusion criteria

• Treatment with any form of lipid lowering drugs, including fish oils.
• Body Mass Index greater than 27.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Alfred Hospital and Baker Heart Research Institute; 🇦🇺 Melbourne, Victoria, Australia